Jasper Therapeutics, Inc. Announces 2024 Annual Meeting of Stockholders
Ticker: JSPRW · Form: DEF 14A · Filed: Apr 22, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | DEF 14A |
| Filed Date | Apr 22, 2024 |
| Risk Level | low |
| Pages | 14 |
| Reading Time | 17 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: Annual Meeting, Proxy Statement, Director Election, Equity Incentive Plan, Auditor Ratification
TL;DR
<b>Jasper Therapeutics, Inc. is holding its 2024 Annual Meeting on June 6, 2024, to elect directors, ratify auditors, and approve an equity incentive plan.</b>
AI Summary
Jasper Therapeutics, Inc. (JSPRW) filed a Proxy Statement (DEF 14A) with the SEC on April 22, 2024. Jasper Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, at 10:00 a.m. Pacific Time. The meeting agenda includes the election of two Class III directors for terms until the 2027 annual meeting. Stockholders will vote on ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024. Approval of the 2024 Equity Incentive Plan is also a key item on the agenda. The company was formerly known as Amplitude Healthcare Acquisition Corp, with a name change date of September 12, 2019.
Why It Matters
For investors and stakeholders tracking Jasper Therapeutics, Inc., this filing contains several important signals. The election of directors and approval of the equity incentive plan are critical for the company's governance and future talent retention. Ratifying the independent auditor ensures continued financial oversight and compliance with regulatory standards.
Risk Assessment
Risk Level: low — Jasper Therapeutics, Inc. shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
Analyst Insight
Stockholders should review the proposals regarding director elections and the equity incentive plan to make informed voting decisions.
Key Numbers
- 2027 — Director Term End (Class III directors to serve until the 2027 annual meeting.)
- 2024 — Fiscal Year End (PricewaterhouseCoopers LLP appointed for fiscal year ending December 31, 2024.)
- 10:00 a.m. Pacific Time — Meeting Time (Time of the Annual Meeting of Stockholders.)
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — Registrant and filer of the proxy statement.
- Amplitude Healthcare Acquisition Corp (company) — Former name of Jasper Therapeutics, Inc.
- PricewaterhouseCoopers LLP (company) — Proposed independent registered public accounting firm.
- June 6, 2024 (date) — Date of the Annual Meeting of Stockholders.
- 2024 Equity Incentive Plan (other) — A plan to be approved by stockholders.
FAQ
When did Jasper Therapeutics, Inc. file this DEF 14A?
Jasper Therapeutics, Inc. filed this Proxy Statement (DEF 14A) with the SEC on April 22, 2024.
What is a DEF 14A filing?
A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Jasper Therapeutics, Inc. (JSPRW).
Where can I read the original DEF 14A filing from Jasper Therapeutics, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Jasper Therapeutics, Inc..
What are the key takeaways from Jasper Therapeutics, Inc.'s DEF 14A?
Jasper Therapeutics, Inc. filed this DEF 14A on April 22, 2024. Key takeaways: Jasper Therapeutics, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 6, 2024, at 10:00 a.m. Pacific Time.. The meeting agenda includes the election of two Class III directors for terms until the 2027 annual meeting.. Stockholders will vote on ratifying the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2024..
Is Jasper Therapeutics, Inc. a risky investment based on this filing?
Based on this DEF 14A, Jasper Therapeutics, Inc. presents a relatively low-risk profile. The filing is a routine proxy statement for an annual meeting and does not contain significant new financial or operational information that would indicate high risk.
What should investors do after reading Jasper Therapeutics, Inc.'s DEF 14A?
Stockholders should review the proposals regarding director elections and the equity incentive plan to make informed voting decisions. The overall sentiment from this filing is neutral.
How does Jasper Therapeutics, Inc. compare to its industry peers?
Jasper Therapeutics operates in the biotechnology sector, focusing on developing therapeutics. Annual meetings are standard for public companies to address corporate governance and strategic matters.
Are there regulatory concerns for Jasper Therapeutics, Inc.?
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
Risk Factors
- Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC regulations regarding proxy solicitations and annual meetings, including timely filing and accurate disclosure.
- Virtual Meeting Logistics [low — operational]: Ensuring a smooth and accessible virtual meeting experience for all stockholders is crucial for participation and engagement.
- Equity Incentive Plan Approval [low — financial]: The approval of the 2024 Equity Incentive Plan is important for attracting and retaining key talent, impacting future compensation costs.
Industry Context
Jasper Therapeutics operates in the biotechnology sector, focusing on developing therapeutics. Annual meetings are standard for public companies to address corporate governance and strategic matters.
Regulatory Implications
The filing is made under Schedule 14A of the Securities Exchange Act of 1934, which governs the solicitation of proxies from shareholders.
What Investors Should Do
- Review the biographies and qualifications of the director nominees.
- Understand the terms and implications of the proposed 2024 Equity Incentive Plan.
- Confirm the company's rationale for ratifying PricewaterhouseCoopers LLP as auditor.
Key Dates
- 2024-06-06: Annual Meeting of Stockholders — To elect directors, ratify auditors, and approve the 2024 Equity Incentive Plan.
Year-Over-Year Comparison
This is a Definitive Proxy Statement (DEF 14A) filed for the 2024 Annual Meeting of Stockholders, indicating a routine corporate event.
Filing Stats: 4,254 words · 17 min read · ~14 pages · Grade level 12.4 · Accepted 2024-04-22 13:13:14
Filing Documents
- ea0204165-01.htm (DEF 14A) — 1777KB
- tproxy_001.jpg (GRAPHIC) — 1323KB
- tproxy_002.jpg (GRAPHIC) — 1240KB
- 0001213900-24-034820.txt ( ) — 5310KB
EXECUTIVE COMPENSATION
EXECUTIVE COMPENSATION   47 EQUITY COMPENSATION PLAN INFORMATION   55
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   57 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS   60 HOUSEHOLDING OF PROXY MATERIALS   62 2023 ANNUAL REPORT AND SEC FILINGS   63 OTHER MATTERS   63 APPENDIX A — 2024 EQUITY INCENTIVE PLAN   A-1 APPENDIX B — 2024 EMPLOYEE STOCK PURCHASE PLAN   B-1 i Table of Contents JASPER THERAPEUTICS, INC. PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS PROCEDURAL MATTERS This proxy statement (this “Proxy Statement”) and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our board of directors (our “Board”) for use at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Jasper Therapeutics, Inc., a Delaware corporation (the “Company” or “Jasper”), and any postponements, adjournments or continuations thereof, or the Annual Meeting. The Annual Meeting will be held virtually on Thursday, June 6, 2024, at 10:00 a.m. Pacific Time via live audio webcast. The Notice of Internet Availability of Proxy Materials (the “Notice”) containing instructions on how to access this Proxy Statement and our Annual Report on Form 10 -K for the fiscal year ended December 31, 2023 (the “Annual Report”) is first being mailed on or about April 25, 2024 to all stockholders entitled to vote at the Annual Meeting. The information provided in the “question and answer” format below is for your convenience only and is merely a summary of the information contained in this Proxy Statement. You should read this entire Proxy Statement carefully. Information contained on, or that can be accessed through, our website is not intended to be incorporated by reference into this Proxy Sta